Anti-tumor Specific Immune Response in Head and Neck Cancers (CORISAT)

Central Hospital, Nancy, France

Status

Unknown

Conditions

Head and Neck Squamous Cell Carcinoma

Treatments

Other: Blood sample

Study type

Observational

Funder types

Other

Identifiers

NCT02881918

PSS2016 / CORISAT-GALLET/SR

Details and patient eligibility

About

The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head & Neck Squamous Cell Carcinoma

Secondary purposes are:

Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs);
Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS
Study of relationship between anti-tumor immune response and clinical stage as well as DFS.

Enrollment

154 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient with Head & Neck Squamous Cell Carcinoma after extension assessment, regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy)
Consent to participate to the study, non-opposition
Affiliation to social security

Exclusion criteria

History of neoplasia, synchronous cancer, auto-immune disease, organ transplantation, chemotherapy
HIV infection
Corticotherapy during 15 days before blood sampling